Paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated enzyme that protects lowdensity lipoprotein (LDL) and HDL from peroxidation. In this study, PON1 activities were determined in patients with erectile dysfunction (ED) to investigate the relationship between ED and atherosclerosis. Forty patients, who had been diagnosed with ED by the medical and sexual anamnesis and routine laboratory tests, were included in the study. Thirty healthy, sexually active, married and age-matched men were selected as the control group. The patients and controls who underwent surgical or medical treatment in 1-week time and had a systemic disease such as malignancy, liver and renal insufficiency, and active infection and who smoked cigarettes were excluded. PON1 activities were measured spectrophotometrically. Unpaired samples t-test, correlation analyses and multiple linear regression analyses were used for statistical analyses. The results are given as mean7standard deviation of mean. The mean ages of the patient and the control groups were 31.0576.90 (range 22-51) and 29.4076.26 (range 19-46), respectively (P ¼ 0.307). Serum PON1 levels of the patient and the control groups were found to be 119.05762.11 and 185.04755.64, respectively. The difference between the groups was quite significant (P ¼ 0.001). Epidemiological and experimental studies indicate that PON1 activation was lower in individuals who had a tendency to develop atherosclerosis due to comorbidities such as diabetes, familial hypercholesterolemia and kidney disease. In this study, PON1 activity level was found to be significantly lower in ED patients than in control group. The decrease of PON1 activity may have a role in the ethiopathogenesis of ED, and the atherosclerosis development may be faster in the patients due to decreased activity of PON1, which is an antiatherogenic enzyme.
Introduction
Penile erection is a hemodynamic process involving increased arterial inflow and restricted venous outflow, coordinated with corpus cavernosum and penile arterial smooth muscle relaxation. Any problem in this mechanism results in erectile dysfunction (ED), and etiology is generally multifactorial. Many disorders related to neurogenic, hormonal or vascular system, and microstructural alterations in the corpus cavernosum (endothelial dysfunction, relaxation loss of smooth muscle cell, fibrosis in smooth muscle and atrophy) give rise to ED. In the etiology of ED, generally organic and psychogenic factors come together. However, if the penis is considered as a specialized vascular bed, it is well-known that vascular reasons dominate in the etiology of ED. 1 During the last 15 years, many unknown topics about basic physiology and pathology of ED were found out especially at the molecular level. Yet, many unexpressed points have been the cynosure for researchers, one of them being the relation of a high-density lipoprotein (HDL)-dependent antioxidant enzyme, PON1, with ED.
PON1 protects low-density lipoprotein (LDL) and HDL from lipid peroxidation, and it is thought of as the primary anti-atherosclerotic component of HDL. There are at least two enzymes on HDL, PON1 [2] [3] [4] and platelet-activating factor acetylhydrolase, 3, 5 that have been shown to prevent the formation of oxidized LDL in vitro. It was shown that PON1 inhibits oxidized lipids and cell-mediator LDL oxidation and protects macrophages from oxidative stress by decreasing oxidized LDL uptake; furthermore, it inhibits cholesterol biosynthesis in macrophages. 6 Several studies have found that PON1 activity is low in individuals susceptible to atherosclerosis development owing to comorbidities such as diabetes mellitus, familial hypercholesterolemia and renal diseases. 7 High serum LDL and other lipid levels, low PON1 activity and HDL levels and togetherness of other major and minor risk factors increase coronary artery diseases (CAD). [8] [9] [10] PON1 activity was measured directly in patients with CAD, and it was approximately half of that of the disease-free control subjects. 11, 12 Our aim in this study is to show whether or not PON1 activity is low in patients with ED by considering the relation of ED and atherosclerosis.
Materials and methods
The protocol was approved by the Institutional Review Board of School of Medicine, Harran University, Turkey. All subjects were informed about the study protocol and written consents were obtained.
Subjects
Forty married patients who had ED for at least 6 months were included in the study. All patients were evaluated using medical history and sexual history with the International Index of Erectile Function (IIEF), physical examination and routine blood analysis. ED domain score was calculated by the IIEF short form (IIEF-5). Subjects were accepted as having ED if ED domain score was p21. Serum fasting blood glucose and hemoglobin A1c, total and free testosterone levels and lipid profiles were measured in the routine blood analysis for the diagnosis of ED.
Thirty volunteer, healthy, sexually active, married and age-matched men who had ED domain score X22 by IIEF short form were selected as the control group.
The study did not include those patients and controls who had a systemic disease such as malignancy, hepatic or renal failure, coronary artery disease, unstable angina, myocardial infarction, hypertension, hyperlipidemia, active infection; those who underwent any operation or cardiovascular intervention within the previous 3 months; those who underwent any medical treatment such as intake of phosphodiesterase type 5 inhibitors and multivitamin drugs in the previous 2 weeks and those who smoked cigarettes.
Blood sample collection Serum samples were collected from patients and controls at 0900 and 1100 hours after an overnight fast. The samples were centrifuged within 2 h after withdrawal and stored at À801C until assayed. Blood tests were made only one time.
Measurement of PON1
PON1 activity was determined by using paraoxon as a substrate and measured by increases in the absorbance at 412 nm due to the formation of 4-nitrophenol as already described. 13 Briefly, the activity was measured at 251C by adding 50 ml of serum to 1 ml of 100 mM Tris-HCl buffer at pH 8.0 containing 2 mM CaCl 2 and 5.5 mM paraoxon. The rate of generation of 4-nitrophenol was determined at 412 nm. Enzymatic activity was calculated by using the molar extinction coefficient 17.100 M À1 cm À1 .
Lipid profile analysis
The levels of triglyceride (TG), total cholesterol (TC), HDL, LDL and very low-density lipoprotein (VLDL) in the serum were determined by using commercially available assay kits (Abbott) with an autoanalyzer (Aeroset, Abbott).
Data analysis
Unpaired samples t-test, correlation analyses and multiple linear regression analyses were used for statistical analyses. Significance was defined as Po0.05. Statistical tests were performed with the SPSS statistical package (SPSS 11.0 for Windows, SPSS Inc., USA).
Results
The results are given as mean7standard deviation of mean. The mean ages of the patient and the control groups were 31.0576.90 years (range 22-51) and 29.4076.26 years (range 19-46), respectively. The mean ages of the groups were similar (P ¼ 0.307). The mean serum fasting blood glucose levels of the patient and the control groups were 109709 and 105710, respectively. The difference between groups was insignificant (P40.05). The mean testosterone levels of the patient and the control groups were 359753 and 377768, respectively. The difference between groups was not significant (P40.05). The mean duration of ED in the patients was 47.10736.58 months (range 6-132).
The mean ED domain scores of the patient and the control groups were 15.2072.98 (range 11-21) and 23.4371.13 (range 22-25), respectively. The difference between groups was significant (P ¼ 0.001).
Whereas the mean levels of TG, TC, LDL and VLDL were significantly high, the mean level of HDL was significantly lower in the patient group than in the control group, and the findings are shown in Table 1 . Serum mean PON1 levels of the patient and the control groups were found to be 119.05762.11 and 185.04755.64, respectively. The difference between Paraoxonase activity in erectile dysfunction H Ciftci et al the groups was quite significant (P ¼ 0.001). The results are summarized in Table 2 .
There was a significant correlation between PON1 activity and HDL-cholesterol levels (r ¼ 0.59, Po0.001; n ¼ 70). The relationship in control groups was higher than that of the patient group (r ¼ 0.60, Po0.001, n ¼ 30; r ¼ 0.31, P ¼ 0.05, n ¼ 40, respectively).
In multiple regression analyses, PON1 and HDLcholesterol were identified as independent variables of ED (b ¼ 0.53, Po0.001; b ¼ 0.28 P ¼ 0.02, respectively).
Discussion
ED can affect the quality of life and general health, and it generally has a multifactorial etiology. Nowadays it is accepted that two factors are responsible and it appears to be the result of complex interaction of organic or psychogenic-based problems. Considering organic etiology, a wide systemic disease spectrum causes the disorder. In a recent study, Morales et al 14 obtained data about ED prevalence and risk factors. Diabetes, hypertension, high cholesterol, peripheral vascular disease, lung disease and cardiac problems were significantly found together with ED. However, when the penis is considered as a vascular bed; vascular reasons predominate in the etiology of ED and it frequently appears along with atherosclerosis. In men over middle age, ED is generally vascular-derived and it forms 40-50% of all etiologic factors. 15, 16 Our opinion is that reasons at the molecular level related to these high-rate etiologic factors should be researched and identified. It is known that atherosclerotic lesions prevent blood flow into cavernosal tissues and cause ED. 17 It causes this with morphological changes such as endothelial damage in vessels, cellular migration and smooth muscle cell proliferation. 18 Also, in the study on rabbit models, it was shown that atherosclerosis and hypercholesterolemia are found together with decreased nitric oxide synthase (NOS) activity, increased contractile tromboxan and prostaglandin production and these disorders detrimentally affect the smooth muscle relaxation. 19 The damaged NO-dependent smooth muscle relaxation in hypercholesterolemia is furthermore related to contractile effects of lowdensity oxidized lipoproteins, secretion of free oxygen radicals and increase of NOS inhibitors. 20 The most important step in the appearance of atherosclerosis is LDL altered with oxidation. LDL, which enters into vessel wall and oxidizes, causes endothelial damage via stimulation of cytokine secretion and inhibition of NO and accelerates atherosclerosis. 21 Furthermore, there is an inverse relationship between HDL level and cardiovascular disease (CVD). It was determined that 1 mg/dl increase of HDL cholesterol decreases the risk of coronary heart disease by 2-3%. 22 PON1 is an antioxidant enzyme that is thought to have a protective role in the atherosclerotic process, while contributing to the protective effect of HDL from atherosclerosis and preventing lipoprotein peroxidation and oxidation of LDL cholesterol. It was determined that PON1 level decreases in people with CVD, hypercholesterolemia, declining years, obesity, menopause and renal failure and in people who smoke. These pathologies mentioned above appear frequently in ED etiopathogenes and this frequent togetherness is invoked to explain the atherosclerotic process. [23] [24] [25] [26] PON1 can also destroy hydrogen peroxide (H 2 O 2 ), a major ROS produced under oxidative stress during atherogenesis, 27 and increase the LDL clearance. 3 In our study, serum PON1 levels are highly positive correlated with serum HDL levels, which were low in the subjects with ED, and thus our opinion is that the patients are exposed to higher atherogenic risk. On the other hand, linear regression analysis results showed that PON1 and HDL-cholesterol parameters were independent variables of ED.
In our study, PON1 activity and HDL was found significantly lower in patients with ED than the control group. This is the first report that shows the relation between PON1 and ED. If significant cut-off value is determined for serum PON1 activity in ED patients in more extensive series, PON1 level will be measured and atherosclerosis, which is the most important and frequent risk factor for ED, will be determined and atherosclerotic process can be monitored and thus patients can be benefited from protective approaches. 
